Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Preferred Shares (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Preferred Shares for 10 consecutive years, with $3000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Preferred Shares changed 0.0% year-over-year to $3000.0, compared with a TTM value of $3000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of $3000.0, changed 0.0% over the prior year.
  • Preferred Shares was $3000.0 for Q4 2025 at Fate Therapeutics, roughly flat from $3000.0 in the prior quarter.
  • Across five years, Preferred Shares topped out at $3000.0 in Q1 2021 and bottomed at $3000.0 in Q1 2021.
  • Average Preferred Shares over 5 years is $3000.0, with a median of $3000.0 recorded in 2021.
  • Peak annual rise in Preferred Shares hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Preferred Shares stood at $3000.0 in 2021, then changed by 0.0% to $3000.0 in 2022, then changed by 0.0% to $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025.
  • Business Quant data shows Preferred Shares for FATE at $3000.0 in Q4 2025, $3000.0 in Q3 2025, and $3000.0 in Q2 2025.